8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 27, 2026·SEC
Instil Bio, Inc.(TIL)Earnings, Financials & Key Ratios
TIL•NASDAQ
$7.75
Price updated Jul 7, 2026
AboutInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.Show more
- Revenue$0
- EBITDA-$52M+25.1%
- Net Income-$71M+3.7%
- EPS (Diluted)-10.70+6.1%
- ROE-50.39%-34.3%
TIL Price & Volume
Instil Bio, Inc. (TIL) stock price & volume — 10-year historical chart
Loading chart...
Severe Liquidity Constraints Threaten Clinical Survival
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Instil Bio remains a pre-commercial entity that has failed to generate any revenue over the last ten quarters, forcing a desperate pivot toward aggressive cost rationalization.
- The company has systematically liquidated its capital-intensive manufacturing infrastructure, evidenced by a collapse in net PPE from $141.1 million in 2023Q4 to $172,000 in 2026Q1.
- Investors should remain cautious as the current cash position of $5.0 million appears insufficient to sustain operations without immediate and dilutive external financing.
Verdict Logic
the company's cash reserves have dwindled to a critical $5.0 million, which, when compared against historical quarterly burn rates, suggests an imminent risk of liquidity exhaustion.
TIL Growth Metrics
Instil Bio, Inc. (TIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.85%
Return on Capital
10 Years-38.57%
5 Years-33.36%
3 Years-30.23%
Last Year-23.29%
TIL Recent Earnings
Instil Bio, Inc. (TIL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.62+0.0%
$0.62
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$1.21+47.6%
$2.31
Rev
—
$2M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$2.01-0.5%
$2.00
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$3.24-88.4%
$1.72
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.62vs $0.62+0.0% | — |
| Q2 2026 | Mar 27, 2026 | $1.21vs $2.31+47.6% | —vs $2M |
| Q4 2025 | Nov 13, 2025 | $2.01vs $2.00-0.5% | — |
| Q3 2025 | Aug 13, 2025 | $3.24vs $1.72-88.4% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Instil Bio, Inc. (TIL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.75 | $52.56M | -0.72 | — | — | -50.39% | — | |
| $4.35 | $1.56B | -3.99 | 60.6% | -123.9% | -50.17% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $5.29 | $10.32M | -0.46 | -13.43% | -299.66% | — | — |
Compare TIL vs Peers
Instil Bio, Inc. (TIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TIL SEC Filings & Documents
Instil Bio, Inc. (TIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TIL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TIL Frequently Asked Questions
Instil Bio, Inc. (TIL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TIL profitable?
Instil Bio, Inc. (TIL) reported a net loss of $47.4M for fiscal year 2025.
Dividend & Returns
What is TIL's return on equity?
Instil Bio, Inc. (TIL) has a return on equity (ROE) of -50.4%. Negative ROE indicates the company is unprofitable.
What is Instil Bio, Inc.'s free cash flow?
Instil Bio, Inc. (TIL) had negative free cash flow of $33.8M in fiscal year 2025, likely due to heavy capital investments.